Janux therapeutics to present virtually at the h.c. wainwright 23rd annual global investor conference

San diego--(business wire)--janux therapeutics, inc. (nasdaq: janx) (janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today announced that janux management will present at the virtual h.c. wainwright 23rd annual global investor conference being held september 13 to 15, 2021. the corporate presentation will be availa
JANX Ratings Summary
JANX Quant Ranking